Table 2.
Description of chemonaïve and recurrent patients recruited for the collection of ascites-derived tumour cells.
| Sample Classification | Diagnosis | Grade | FIGO Stage | Treatment | Age at Diagnosis | Survival |
|---|---|---|---|---|---|---|
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IV | None | 76 | 7 months at death |
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IIIc | None | 64 | 1 month at death |
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IV | None | 83 | 1 year 10 months at death |
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IIIc | None | 41 | 1 year 7 months ALC |
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IIIc | None | 52 | 1 year 9 months ALC |
| Chemonaïve | Carcinoma NOS | G3- poorly differentiated | IIc | None | 62 | 2 years 2 months ALC |
| Chemonaïve | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IIIc | None | 63 | 9 months ALC |
| Chemonaïve | Adenocarcinoma NOS | G3- poorly differentiated | IV | None | 52 | 1 year ALC |
| Recurrent | Serous cystadenocarcinoma NOS | G3- poorly differentiated | IV | Carboplatin and Paclitaxel 6 cycles Carboplatin 4 cycles Cisplatin 2 cycles Doxorubicin Pegylated Liposomal 1 cycle |
50 | 1 year 10 months at death |
| Recurrent | Serous surface papillary carcinoma (Gr3) | G3- poorly differentiated | IIIc | ICON6 Trial 8 cycles Carboplatin and Paclitaxel 6 cycles OVAR16/VEG110655 Trial 4 cycles Cisplatin 6 cycles Doxorubicin Pegylated Liposomal 6 cycles Docetaxel 3 cycles REZOLVE Study 3 cycles Paclitaxel 1 cycl |
59 | 4 years 7 months at death |
| Recurrent | Serous cystadenocarcinoma NOS (Gr3) | G3- poorly differentiated | IV | REZOLVE Study 5 cycles Unspecified Regimen 7 cycles Doxorubicin Pegylated Liposomal 6 cycles Paclitaxel 5 cycles Cisplatin 6 cycles | 57 | 5 years 8 months at death |
| Recurrent | Serous cystadenocarcinoma NOS (Gr3) | G3- poorly differentiated | IIIc | Carboplatin and Paclitaxel 6 cycles PrePARE Study 2 cycles Cisplatin 5 cycles Unspecified Regimen 6 cycles Doxorubicin Pegylated Liposomal 5 cycles |
61 | 2 years 2 months at death |
| Recurrent | Papillary serous adenocarcinoma (Gr2) | G1- well differentiated | IIIc | Carboplatin and Paclitaxel 3 cycles Doxorubicin Pegylated Liposomal 4 cycles | 31 | 9 months at death |
| Recurrent | Papillary serous adenocarcinoma (Gr2) | G3- poorly differentiated | IIc | Carboplatin and Paclitaxel 6 cycles Lilly Trial 3 cycles Cisplatin 1 cycle Doxorubicin Pegylated Liposomal 3 cycles Paclitaxel 2 cycles REZOLVE Study 1 cycle |
68 | 6 years 1 month at death |